Versant Ventures

Granite Bio is a biotechnology company focused on developing novel monoclonal antibodies aimed at treating inflammatory, autoimmune, and fibrotic disorders. The company specializes in creating therapeutic antibodies that deplete pathogenic cells and selectively target key biological processes associated with these diseases. By concentrating on these advanced treatments, Granite Bio contributes to the broader fields of biotechnology, pharmaceuticals, and diagnostics, ultimately seeking to improve patient outcomes in complex medical conditions.

Light Horse Therapeutics is a biotechnology company specializing in the application of gene editing to small-molecule drug discovery. It develops innovative methods to target the root causes of severe and life-threatening diseases, with an initial focus on challenging oncology targets. The company's advanced platform identifies critical functional domains within disease-related proteins, enabling the development of novel therapies.

858 Therapeutics is a biotechnology company dedicated to the discovery of small molecule therapeutics aimed at treating cancers and other diseases, particularly those resistant to existing therapies. The company employs innovative strategies in areas such as synthetic lethality, innate immunity, and RNA modulation to develop its therapeutic candidates. Its lead program focuses on a PARG inhibitor, which is currently in early clinical development. By leveraging its platform to investigate the role of RNA modifying proteins in disease biology, 858 Therapeutics is generating a pipeline of targeted small molecules that address critical unmet medical needs in oncology and immunology.

Borealis Biosciences is a discovery-stage biotechnology company focused on developing next-generation RNA-based medicines specifically for kidney diseases. The company utilizes its expertise in molecular and cellular biology, chemistry, and analytical capabilities to identify target opportunities within different patient subsets affected by kidney conditions. By refining methods for delivering RNA medicines to specific cell types, Borealis Biosciences aims to tackle significant unmet medical needs in the treatment of kidney diseases.

LENZ Therapeutics is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative ophthalmic therapies. It focuses on addressing vision-related issues, particularly presbyopia, which affects the near vision of individuals, especially those over the age of 45. The company's primary product is an aceclidine-based eye drop designed to restore near vision loss associated with this condition. Through its advancements in ophthalmic pharmaceuticals, LENZ Therapeutics aims to improve the quality of life for those impacted by vision challenges.

FireFly Bio focuses on developing Degrader Antibody Conjugates (DACs), a novel approach that merges the benefits of antibody-drug conjugates with selective protein degraders. This proprietary healthcare platform is designed to enhance cancer treatment by ensuring the precise delivery of therapeutic agents to targeted tissues. By leveraging advanced bioconjugate technologies, FireFly Bio aims to create more effective and targeted medicines that improve patient outcomes in the fight against cancer.

Enterprise Therapeutics, established in 2014 and headquartered in Brighton, UK, is a drug discovery company focused on developing therapies for respiratory diseases. Its primary focus is on chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company aims to create novel treatments that target the underlying mechanisms of mucus congestion, reducing lung infections and enhancing patients' quality of life.

Gate Bioscience is a biotechnology company focused on developing small molecule drugs to selectively target and eliminate harmful extracellular proteins at their source within cells. The company's innovative approach combines a proprietary library of molecular gates, specialized assays, and deep expertise in secretory pathway biology, enabling precise, rapid, and repeatable drug discovery. This unique methodology allows Gate Bioscience to address a broad spectrum of diseases using a single therapeutic mechanism, with the potential to revolutionize the treatment of intractable diseases.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company specializes in targeted radiotherapies that employ purpose-built vectors to deliver high-energy radioisotopes directly to tumors and metastatic lesions. This innovative approach aims to provide more effective treatment options for patients, capitalizing on the significant therapeutic and commercial potential of TATs. With the nuclear medicine market projected to grow substantially, Abdera's targeted therapies are positioned to play a crucial role in the evolving landscape of cancer treatment.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company specializes in targeted radiotherapies that employ purpose-built vectors to deliver high-energy radioisotopes directly to tumors and metastatic lesions. This innovative approach aims to provide more effective treatment options for patients, capitalizing on the significant therapeutic and commercial potential of TATs. With the nuclear medicine market projected to grow substantially, Abdera's targeted therapies are positioned to play a crucial role in the evolving landscape of cancer treatment.

Belharra Therapeutics is a privately held drug discovery company based in the San Francisco Bay Area, primarily operating out of San Diego. The company utilizes a novel photoaffinity-based chemoproteomics platform that allows its scientists to identify small molecule drug candidates for any binding site on any protein, in various conformational states, and across different cell types. By integrating innovative biology, medicinal chemistry, and bioinformatics, Belharra aims to discover transformative, first-in-class medicines targeting serious diseases and conditions. Through its advanced drug discovery approach, the company seeks to revolutionize the identification of novel therapeutic starting points, ultimately benefiting patients in need of effective treatments.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

Vector Biopharma is a biopharmaceutical company specializing in immuno-oncology. The company utilizes advanced gene precision delivery technology, employing engineered adenoviral vectors to facilitate cell- and tissue-specific delivery of genes and regulators. This innovative approach enables tunable expression, allowing for enhanced safety, efficacy, and specificity of biologics. By focusing on these cutting-edge techniques, Vector Biopharma aims to support the healthcare industry in discovering new and potent drugs, ultimately transforming treatment options in the field of immunotherapy.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule medicines aimed at treating autoimmune diseases, inflammatory diseases, and cancer by targeting the innate immune system. The company employs a structural immunology platform that provides deep insights into the mechanisms and molecular structures involved in immune responses. This platform integrates proprietary protein engineering capabilities with advanced rational and structure-based drug design tools, allowing for precise targeting of the innate immune system. Ventus is actively building a pipeline of drug programs that address critical targets within this system, particularly proteins involved in inflammasome and nucleic acid-sensing signaling pathways, thereby enabling the treatment of both acute and chronic inflammatory and immune-related conditions.

Nested Therapeutics is a Cambridge-based biotech company founded in 2021, specializing in the development of precision oncology therapies. The firm focuses on discovering and creating small-molecule drugs that target specific cancer genes and driver mutations. By leveraging advanced techniques in genomics, computational chemistry, proteomics, and artificial intelligence, Nested Therapeutics aims to identify druggable pockets within mutation clusters. This approach allows for the development of novel therapies that enable healthcare professionals to provide more effective and targeted treatments for cancer patients.

858 Therapeutics is a biotechnology company dedicated to the discovery of small molecule therapeutics aimed at treating cancers and other diseases, particularly those resistant to existing therapies. The company employs innovative strategies in areas such as synthetic lethality, innate immunity, and RNA modulation to develop its therapeutic candidates. Its lead program focuses on a PARG inhibitor, which is currently in early clinical development. By leveraging its platform to investigate the role of RNA modifying proteins in disease biology, 858 Therapeutics is generating a pipeline of targeted small molecules that address critical unmet medical needs in oncology and immunology.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

LENZ Therapeutics is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative ophthalmic therapies. It focuses on addressing vision-related issues, particularly presbyopia, which affects the near vision of individuals, especially those over the age of 45. The company's primary product is an aceclidine-based eye drop designed to restore near vision loss associated with this condition. Through its advancements in ophthalmic pharmaceuticals, LENZ Therapeutics aims to improve the quality of life for those impacted by vision challenges.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule medicines aimed at treating autoimmune diseases, inflammatory diseases, and cancer by targeting the innate immune system. The company employs a structural immunology platform that provides deep insights into the mechanisms and molecular structures involved in immune responses. This platform integrates proprietary protein engineering capabilities with advanced rational and structure-based drug design tools, allowing for precise targeting of the innate immune system. Ventus is actively building a pipeline of drug programs that address critical targets within this system, particularly proteins involved in inflammasome and nucleic acid-sensing signaling pathways, thereby enabling the treatment of both acute and chronic inflammatory and immune-related conditions.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative therapeutics to address significant unmet medical needs. Established in 2013, Vividion utilizes a pioneering platform for proteome-wide small molecule drug discovery, which combines advanced synthetic chemistry techniques with chemical proteomics. This approach allows the company to expand the druggable proteome and target challenging proteins, ultimately enabling the discovery of transformative treatments for serious illnesses. Vividion's scientific foundation stems from experts in chemical biology and synthetic chemistry at The Scripps Research Institute, reflecting its commitment to advancing therapeutics that can significantly improve patient outcomes.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, founded in 2016. The company specializes in developing proprietary bispecific antibodies aimed at engaging gamma-delta T cells for the treatment of both hematological and solid cancers. Its innovative platform, known as the Gammabody platform, is designed to create next-generation bispecific antibodies that activate the immune system to recognize and eliminate tumor cells. By harnessing the potential of γδ T cells, Lava Therapeutics aims to produce potent, safe, and cost-effective biopharmaceuticals that enhance the body's ability to combat cancer, thereby transforming the landscape of cancer treatment.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule medicines aimed at treating autoimmune diseases, inflammatory diseases, and cancer by targeting the innate immune system. The company employs a structural immunology platform that provides deep insights into the mechanisms and molecular structures involved in immune responses. This platform integrates proprietary protein engineering capabilities with advanced rational and structure-based drug design tools, allowing for precise targeting of the innate immune system. Ventus is actively building a pipeline of drug programs that address critical targets within this system, particularly proteins involved in inflammasome and nucleic acid-sensing signaling pathways, thereby enabling the treatment of both acute and chronic inflammatory and immune-related conditions.

Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, specializing in the discovery and development of novel therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which combines genome-wide and CRISPR-enabled technology, the company systematically identifies targeted cancer therapies addressing genomic instability, particularly in DNA damage repair. Its lead candidate, RP-3500, is an oral small molecule inhibitor designed to treat solid tumors with specific DNA damage repair-related genomic alterations. Additionally, Repare is advancing a CCNE1-SL inhibitor program targeting tumors with CCNE1 amplification, along with a Polymerase Theta program focused on BRCA mutations and related genomic alterations. Founded in 2016, the company aims to improve cancer treatment by leveraging innovative drug discovery methods and addressing the unique vulnerabilities of tumor cells.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative therapeutics to address significant unmet medical needs. Established in 2013, Vividion utilizes a pioneering platform for proteome-wide small molecule drug discovery, which combines advanced synthetic chemistry techniques with chemical proteomics. This approach allows the company to expand the druggable proteome and target challenging proteins, ultimately enabling the discovery of transformative treatments for serious illnesses. Vividion's scientific foundation stems from experts in chemical biology and synthetic chemistry at The Scripps Research Institute, reflecting its commitment to advancing therapeutics that can significantly improve patient outcomes.

Oyster Point Pharma, Inc., established in 2015 and headquartered in Princeton, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular surface diseases. Its lead product candidate, OC-01, is a nasal spray formulated as a highly selective nicotinic acetylcholine receptor (nAChR) agonist, currently in Phase III trials for treating the signs and symptoms of dry eye disease, a chronic condition affecting over 30 million Americans. OC-01's novel mechanism of action stimulates tear production by activating the trigeminal parasympathetic pathway, re-establishing tear film homeostasis.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.

Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.

Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.

Aprea is a biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea Therapeutics was established in 2003 in Stockholms Lan, Sweden by Klas Wiman and Galina Selivanova.

Gotham Therapeutics is a biotechnology company based in New York that focuses on developing a novel class of drugs targeting epitranscriptomics machinery. Founded in 2017, the company aims to provide new treatment options for patients with cancers, autoimmune disorders, and neurodegenerative diseases. Its approach involves creating small molecules that modify the activity of messenger ribonucleic acid (mRNA) to influence protein transcription. This innovative strategy allows Gotham Therapeutics to potentially optimize therapeutic outcomes for individuals suffering from serious health conditions.

Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.

Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, founded in 2016. The company specializes in developing proprietary bispecific antibodies aimed at engaging gamma-delta T cells for the treatment of both hematological and solid cancers. Its innovative platform, known as the Gammabody platform, is designed to create next-generation bispecific antibodies that activate the immune system to recognize and eliminate tumor cells. By harnessing the potential of γδ T cells, Lava Therapeutics aims to produce potent, safe, and cost-effective biopharmaceuticals that enhance the body's ability to combat cancer, thereby transforming the landscape of cancer treatment.

Enterprise Therapeutics, established in 2014 and headquartered in Brighton, UK, is a drug discovery company focused on developing therapies for respiratory diseases. Its primary focus is on chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company aims to create novel treatments that target the underlying mechanisms of mucus congestion, reducing lung infections and enhancing patients' quality of life.

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company headquartered in San Diego, California, dedicated to the discovery, development, and commercialization of innovative therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist currently undergoing Phase I clinical trials aimed at treating acromegaly and neuroendocrine tumors. In addition to paltusotine, Crinetics is developing several other therapeutics, including CRN01941, an oral selective nonpeptide sst2 biased agonist for neuroendocrine tumors, and an oral somatostatin type 5 receptor agonist for congenital hyperinsulinism. The company is also working on an oral adrenocorticotrophic hormone antagonist for conditions such as Cushing’s syndrome and congenital adrenal hyperplasia. Founded in 2008, Crinetics Pharmaceuticals is focused on leveraging its internal discovery efforts to create effective treatments while utilizing hormonal biomarker endpoints to enhance the efficiency and cost-effectiveness of its clinical studies.

Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

Oyster Point Pharma, Inc., established in 2015 and headquartered in Princeton, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular surface diseases. Its lead product candidate, OC-01, is a nasal spray formulated as a highly selective nicotinic acetylcholine receptor (nAChR) agonist, currently in Phase III trials for treating the signs and symptoms of dry eye disease, a chronic condition affecting over 30 million Americans. OC-01's novel mechanism of action stimulates tear production by activating the trigeminal parasympathetic pathway, re-establishing tear film homeostasis.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, specializing in the discovery and development of novel therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which combines genome-wide and CRISPR-enabled technology, the company systematically identifies targeted cancer therapies addressing genomic instability, particularly in DNA damage repair. Its lead candidate, RP-3500, is an oral small molecule inhibitor designed to treat solid tumors with specific DNA damage repair-related genomic alterations. Additionally, Repare is advancing a CCNE1-SL inhibitor program targeting tumors with CCNE1 amplification, along with a Polymerase Theta program focused on BRCA mutations and related genomic alterations. Founded in 2016, the company aims to improve cancer treatment by leveraging innovative drug discovery methods and addressing the unique vulnerabilities of tumor cells.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative therapeutics to address significant unmet medical needs. Established in 2013, Vividion utilizes a pioneering platform for proteome-wide small molecule drug discovery, which combines advanced synthetic chemistry techniques with chemical proteomics. This approach allows the company to expand the druggable proteome and target challenging proteins, ultimately enabling the discovery of transformative treatments for serious illnesses. Vividion's scientific foundation stems from experts in chemical biology and synthetic chemistry at The Scripps Research Institute, reflecting its commitment to advancing therapeutics that can significantly improve patient outcomes.

Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.

Jecure Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small-molecule therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. Established in 2015 and operating as a subsidiary of Genentech, Inc. since 2018, the company specializes in innovative drug discovery programs aimed at addressing serious inflammatory diseases. Jecure's therapeutics work by blocking inflammasome activation and disrupting the inflammation processes that lead to liver cell injury and death. The company utilizes advanced methodologies, including SiRNA-based murine fibrosis models for target identification and validation, as well as unique in-vivo screening models that replicate key features of NASH. This approach enables the identification of drug candidates capable of intervening throughout the disease progression, facilitating a clearer path for translational development.

Aprea is a biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea Therapeutics was established in 2003 in Stockholms Lan, Sweden by Klas Wiman and Galina Selivanova.

Kyras Therapeutics Inc. is a biotechnology company based in New York, specializing in the development of drugs aimed at treating incurable cancers and developmental disorders. Founded in 2015, the company focuses on addressing conditions linked to mutations in RAS genes, which are responsible for a significant percentage of various cancers, including pancreatic, colorectal, and lung cancers. By targeting these mutations, Kyras Therapeutics aims to provide effective treatments that can potentially cure patients suffering from these challenging health issues.

Inception IBD is focused on translating academic discoveries in the field of IBD

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company headquartered in San Diego, California, dedicated to the discovery, development, and commercialization of innovative therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist currently undergoing Phase I clinical trials aimed at treating acromegaly and neuroendocrine tumors. In addition to paltusotine, Crinetics is developing several other therapeutics, including CRN01941, an oral selective nonpeptide sst2 biased agonist for neuroendocrine tumors, and an oral somatostatin type 5 receptor agonist for congenital hyperinsulinism. The company is also working on an oral adrenocorticotrophic hormone antagonist for conditions such as Cushing’s syndrome and congenital adrenal hyperplasia. Founded in 2008, Crinetics Pharmaceuticals is focused on leveraging its internal discovery efforts to create effective treatments while utilizing hormonal biomarker endpoints to enhance the efficiency and cost-effectiveness of its clinical studies.

PIQUR Therapeutics AG is a clinical-stage pharmaceutical company based in Basel, Switzerland, specializing in the discovery and development of innovative anti-cancer drugs. Founded in 2011, the company focuses on therapies that target lipid kinase (PI3K) and mTOR, both of which are established drug targets in oncology. PIQUR has developed a robust pipeline of compounds, including its lead product, bimiralisib, which aims for dual inhibition of the PI3K/mTOR pathway. The company's mission is to create breakthrough targeted medicines for oncology and dermatology, addressing the treatment of various cancers and genetic diseases. With a secured patent portfolio protecting many of its chemical compounds, PIQUR Therapeutics is dedicated to enhancing the quality of life for cancer patients through advanced therapeutic options.

Laguna Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and marketing small molecule pharmaceuticals, particularly vanoxerine, which is a therapeutic candidate for treating atrial fibrillation and atrial flutter. Originally founded in 2006 as ChanRx Corp., the company rebranded to Laguna Pharmaceuticals in February 2015. Headquartered in La Jolla, California, Laguna Pharmaceuticals aims to address the medical needs associated with atrial fibrillation, a prevalent arrhythmia linked to serious cardiovascular events such as heart attacks and strokes.

AAVLife is a gene therapy company based in Paris, France, founded in 2014. The company focuses on developing therapies for Friedreich's Ataxia Cardiomyopathy, a genetic disorder that leads to severe neurological and cardiac symptoms. AAVLife's innovative approach utilizes an adeno-associated virus to deliver a normal gene into cardiac tissue, which has shown promise in restoring cardiac function and reversing heart enlargement in preclinical models. The company has made significant progress in its research to determine optimal dosing and administration routes for upcoming clinical trials. AAVLife aims to engage with regulatory authorities to finalize the design of these trials, with plans to initiate an observational study and a Phase I/II clinical trial. Through its efforts, AAVLife is committed to advancing gene therapy solutions for patients affected by this life-threatening condition, emphasizing its dedication to patient communities and the organizations that support them.

PIQUR Therapeutics AG is a clinical-stage pharmaceutical company based in Basel, Switzerland, specializing in the discovery and development of innovative anti-cancer drugs. Founded in 2011, the company focuses on therapies that target lipid kinase (PI3K) and mTOR, both of which are established drug targets in oncology. PIQUR has developed a robust pipeline of compounds, including its lead product, bimiralisib, which aims for dual inhibition of the PI3K/mTOR pathway. The company's mission is to create breakthrough targeted medicines for oncology and dermatology, addressing the treatment of various cancers and genetic diseases. With a secured patent portfolio protecting many of its chemical compounds, PIQUR Therapeutics is dedicated to enhancing the quality of life for cancer patients through advanced therapeutic options.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions. The company offers innovative treatments for diseases such as rheumatoid arthritis, metabolic disorders, fibrosis, and nonalcoholic steatohepatitis. Utilizing a proprietary technology platform, Bird Rock Bio focuses on developing monoclonal antibodies that target G-protein coupled receptors (GPCRs), which are critical for therapeutic specificity. Among its key products is RYI-008, a highly selective antibody targeting IL-6, a cytokine involved in inflammation and cancer. Bird Rock Bio aims to meet the medical needs of patients in China while also seeking to create global market opportunities. The company, originally known as RuiYi Inc., was established in 2006 and is headquartered in La Jolla, California, with a research facility in Shanghai, China.

Inception Sciences, Inc. is a drug discovery company established in 2011, located in San Diego, California, with additional research facilities in Vancouver and Saint Laurent, Canada. The company specializes in developing small molecule therapies aimed at addressing diseases and disorders that have significant unmet medical needs. By collaborating with academic experts, Inception Sciences translates biological insights into innovative and targeted drug candidates. The team boasts a strong history in drug discovery, having contributed to the development of clinical-stage compounds for conditions such as fibrosis, asthma, and chronic obstructive pulmonary disease (COPD) while previously working with notable pharmaceutical firms.

Immune Design Corp. is a clinical-stage immunotherapy company headquartered in Seattle, Washington, that specializes in developing innovative treatments for cancer through in vivo methods that empower the immune system to combat disease. The company utilizes its ZVex and GLAAS discovery platforms to create a new generation of immune-based products. Its primary product candidate, G100, is currently undergoing Phase II clinical trials for follicular non-Hodgkin lymphoma, while another candidate, CMB305, focuses on enhancing tumor-specific cytotoxic T cells. Immune Design's research aims to overcome limitations of existing oncological therapies, and the company has established collaboration and license agreements with Sanofi Pasteur. Founded in 2008, Immune Design operates as a subsidiary of Merck & Co., Inc.

Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in providing advanced diagnostic solutions for cancer and other diseases. Its product offerings include the Afirma Genomic Sequencing Classifier, which helps identify benign thyroid nodules, the Percepta Genomic Sequencing Classifier for lung cancer, and the Envisia Genomic Classifier for distinguishing idiopathic pulmonary fibrosis from other interstitial lung diseases. Additionally, Veracyte offers the Prosigna Breast Cancer Prognostic Gene Signature Assay, which assesses the risk of distant recurrence in breast cancer patients. The company's tests leverage advances in genomic science to reduce the need for invasive procedures, thereby facilitating timely and accurate treatment decisions. Veracyte has established collaborations with Johnson & Johnson Innovation and Loxo Oncology to enhance its diagnostic capabilities and develop targeted therapies for genetically defined cancers. Since its incorporation in 2006 and subsequent name change in 2008, Veracyte has aimed to improve patient care through innovative genomic testing.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

Achaogen, Inc. is a biopharmaceutical company focused on developing antibacterial agents to combat multi-drug resistant (MDR) gram-negative infections. The company's primary product, plazomicin, is designed to treat serious bacterial infections caused by MDR enterobacteriaceae, particularly carbapenem-resistant strains. Additionally, Achaogen is working on C-Scape, an orally-administered combination therapy targeting infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established several collaboration agreements, including partnerships with Thermo Fisher Scientific for assay development, and Ionis Pharmaceuticals for the advancement of aminoglycoside antibacterial compounds. The company generates revenue primarily through government contracts for research and development. Founded in 2002 and based in South San Francisco, California, Achaogen filed for Chapter 11 bankruptcy in April 2019, transitioning to a liquidation plan in May 2020.

Flexion Therapeutics, Inc. is a biopharmaceutical company based in Burlington, Massachusetts, that specializes in the discovery, development, and commercialization of therapies for musculoskeletal conditions, particularly osteoarthritis. The company's primary product, ZILRETTA, is an intra-articular injection approved for managing knee pain associated with osteoarthritis in the United States. In addition to ZILRETTA, Flexion is advancing several other innovative treatments, including FX201, a gene therapy aimed at producing an anti-inflammatory protein to alleviate knee pain, and FX301, a NaV1.7 inhibitor designed for post-operative pain management. Founded in 2007, Flexion Therapeutics aims to enhance the effectiveness of local therapies while partnering with other pharmaceutical and biotechnology companies to expand its product offerings and share development risks.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Synosia Therapeutics is a privately-owned company focused on developing and commercializing products to address unmet medical needs in the fields of psychiatry and neurology. The company has a pipeline that includes six clinical-stage compounds, which have been acquired through partnerships with major pharmaceutical companies. Two of these compounds are existing marketed drugs that are undergoing testing for new indications, aiming to expand their applications to treat neurological and psychiatric conditions such as anxiety and Parkinson's disease. In addition to its product development efforts, Synosia Therapeutics also offers clinical development programs and research services.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

Okairos AG is a biopharmaceutical company that specializes in the discovery and development of genetic T-cell vaccines, with a significant focus on combating the hepatitis C virus. The company is also involved in providing health and allied services. Headquartered in Basel, Switzerland, Okairos operates in Rome and Naples, Italy. It has expertise in gene delivery technologies and scalable viral-vector manufacturing processes, which facilitate the advancement of vaccines and advanced therapies. By utilizing state-of-the-art GMP facilities, Okairos supports biotech companies in transitioning their genetic vaccines and medicinal products from preclinical stages to commercial readiness.

Immune Design Corp. is a clinical-stage immunotherapy company headquartered in Seattle, Washington, that specializes in developing innovative treatments for cancer through in vivo methods that empower the immune system to combat disease. The company utilizes its ZVex and GLAAS discovery platforms to create a new generation of immune-based products. Its primary product candidate, G100, is currently undergoing Phase II clinical trials for follicular non-Hodgkin lymphoma, while another candidate, CMB305, focuses on enhancing tumor-specific cytotoxic T cells. Immune Design's research aims to overcome limitations of existing oncological therapies, and the company has established collaboration and license agreements with Sanofi Pasteur. Founded in 2008, Immune Design operates as a subsidiary of Merck & Co., Inc.

Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in providing advanced diagnostic solutions for cancer and other diseases. Its product offerings include the Afirma Genomic Sequencing Classifier, which helps identify benign thyroid nodules, the Percepta Genomic Sequencing Classifier for lung cancer, and the Envisia Genomic Classifier for distinguishing idiopathic pulmonary fibrosis from other interstitial lung diseases. Additionally, Veracyte offers the Prosigna Breast Cancer Prognostic Gene Signature Assay, which assesses the risk of distant recurrence in breast cancer patients. The company's tests leverage advances in genomic science to reduce the need for invasive procedures, thereby facilitating timely and accurate treatment decisions. Veracyte has established collaborations with Johnson & Johnson Innovation and Loxo Oncology to enhance its diagnostic capabilities and develop targeted therapies for genetically defined cancers. Since its incorporation in 2006 and subsequent name change in 2008, Veracyte has aimed to improve patient care through innovative genomic testing.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Flexion Therapeutics, Inc. is a biopharmaceutical company based in Burlington, Massachusetts, that specializes in the discovery, development, and commercialization of therapies for musculoskeletal conditions, particularly osteoarthritis. The company's primary product, ZILRETTA, is an intra-articular injection approved for managing knee pain associated with osteoarthritis in the United States. In addition to ZILRETTA, Flexion is advancing several other innovative treatments, including FX201, a gene therapy aimed at producing an anti-inflammatory protein to alleviate knee pain, and FX301, a NaV1.7 inhibitor designed for post-operative pain management. Founded in 2007, Flexion Therapeutics aims to enhance the effectiveness of local therapies while partnering with other pharmaceutical and biotechnology companies to expand its product offerings and share development risks.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Clovis Oncology, Inc. is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of anti-cancer agents in the United States, Europe, and other international markets. The company is known for its product Rubraca (rucaparib), an oral small molecule inhibitor designed to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Additionally, Clovis is developing lucitanib, an oral inhibitor that targets various tyrosine kinase receptors associated with tumor growth. The company utilizes precision medicine and companion diagnostics to ensure that therapies are directed toward patients most likely to benefit from them. Clovis Oncology distributes its products primarily through specialty distributors and pharmacy providers. Founded in 2009 and headquartered in Boulder, Colorado, the company has established partnerships and licensing agreements with multiple pharmaceutical organizations, enhancing its ability to innovate within the oncology sector.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, that specializes in the development of engineered precision biologics using an advanced genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, leading to the creation of next-generation therapeutics, including antibody drug conjugates (ADCs), bispecific antibodies, and long-acting therapeutic peptides. Ambrx's development pipeline features several product candidates, such as ARX788, ARX517, and ARX305, which target various therapeutic areas, including oncology, metabolic, and cardiovascular diseases. The company collaborates with organizations like MabSpace Biosciences, BeiGene, and NovoCodex Biopharmaceuticals to enhance its research and development efforts. Founded in 2003, Ambrx aims to optimize the efficacy, safety, and usability of its biopharmaceutical products.

Cadence Pharmaceuticals is a biopharmaceutical company that specializes in the development and commercialization of proprietary product candidates for hospital use. The company focuses on in-licensing innovative therapies to enhance patient care. Its primary product is OFIRMEV, an intravenous formulation of acetaminophen designed for the management of pain and the reduction of fever in both adults and children. Cadence has made significant progress with OFIRMEV, having resubmitted a New Drug Application to the FDA, which has assigned a Prescription Drug User Fee Act action date for review.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions. The company offers innovative treatments for diseases such as rheumatoid arthritis, metabolic disorders, fibrosis, and nonalcoholic steatohepatitis. Utilizing a proprietary technology platform, Bird Rock Bio focuses on developing monoclonal antibodies that target G-protein coupled receptors (GPCRs), which are critical for therapeutic specificity. Among its key products is RYI-008, a highly selective antibody targeting IL-6, a cytokine involved in inflammation and cancer. Bird Rock Bio aims to meet the medical needs of patients in China while also seeking to create global market opportunities. The company, originally known as RuiYi Inc., was established in 2006 and is headquartered in La Jolla, California, with a research facility in Shanghai, China.

Synosia Therapeutics is a privately-owned company focused on developing and commercializing products to address unmet medical needs in the fields of psychiatry and neurology. The company has a pipeline that includes six clinical-stage compounds, which have been acquired through partnerships with major pharmaceutical companies. Two of these compounds are existing marketed drugs that are undergoing testing for new indications, aiming to expand their applications to treat neurological and psychiatric conditions such as anxiety and Parkinson's disease. In addition to its product development efforts, Synosia Therapeutics also offers clinical development programs and research services.

Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. Paclitaxel is an anti-proliferative drug commonly used to prevent arterial restenosis. Lutonix DCB is very similar to a standard angioplasty balloon, but contains a special coating consisting of paclitaxel and a proprietary carrier that facilitates the drug’s transfer to the arterial wall upon inflation. This highly efficient formulation allows Lutonix DCB to deliver a therapeutic dose to the artery wall, while keeping the dose of paclitaxel on the balloon as low as possible. A lower balloon drug load minimizes systemic drug exposure and is designed to maximize safety.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

Immune Design Corp. is a clinical-stage immunotherapy company headquartered in Seattle, Washington, that specializes in developing innovative treatments for cancer through in vivo methods that empower the immune system to combat disease. The company utilizes its ZVex and GLAAS discovery platforms to create a new generation of immune-based products. Its primary product candidate, G100, is currently undergoing Phase II clinical trials for follicular non-Hodgkin lymphoma, while another candidate, CMB305, focuses on enhancing tumor-specific cytotoxic T cells. Immune Design's research aims to overcome limitations of existing oncological therapies, and the company has established collaboration and license agreements with Sanofi Pasteur. Founded in 2008, Immune Design operates as a subsidiary of Merck & Co., Inc.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions. The company offers innovative treatments for diseases such as rheumatoid arthritis, metabolic disorders, fibrosis, and nonalcoholic steatohepatitis. Utilizing a proprietary technology platform, Bird Rock Bio focuses on developing monoclonal antibodies that target G-protein coupled receptors (GPCRs), which are critical for therapeutic specificity. Among its key products is RYI-008, a highly selective antibody targeting IL-6, a cytokine involved in inflammation and cancer. Bird Rock Bio aims to meet the medical needs of patients in China while also seeking to create global market opportunities. The company, originally known as RuiYi Inc., was established in 2006 and is headquartered in La Jolla, California, with a research facility in Shanghai, China.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

MedManage Systems is an online provider of prescription drug sampling solutions. The company's Samples On Demand service facilitates connections between pharmaceutical manufacturers and healthcare providers through a network of physician portals. This service enables users to access medication samples conveniently and efficiently, improving the distribution of pharmaceutical products. By offering on-demand access to drug samples, MedManage enhances the ability of pharmaceutical brands to reach their customers while streamlining the sampling process for healthcare professionals.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.

NovaCardia is a pharmaceutical company specializing in the development of drugs for cardiovascular diseases. With a strong focus on acute cardiac care, the company is dedicated to enhancing patient outcomes through the creation and commercialization of innovative small molecule therapies. Among its key projects is an oral formulation of KW-3902, aimed at treating chronic congestive heart failure. NovaCardia's expertise in cardiovascular drug development positions it to make significant contributions to the field and improve the quality of care for patients suffering from these conditions.

Amira Pharmaceuticals is a small molecule pharmaceutical company dedicated to the discovery and early development of innovative drugs targeting inflammatory diseases. The company's research team leverages deep insights into bioactive lipid pathways and complex signaling mechanisms that influence various conditions, including asthma, chronic obstructive pulmonary disease, cardiovascular issues, and fibrotic diseases. Through its focused approach, Amira aims to develop effective treatments that address unmet medical needs in the realm of inflammation-related health challenges.